Adverse Event | Contraceptive | AE frequency (%) | Sample size (n) | Publication | |
Men | Women | ||||
Acne | Injectable combination male contraceptive | 45.9 | 320 | Behre et al 20168 | |
COC | 5.1 | 1723 | Ortho Tri-Cyclen Lo11 | ||
IUS | 6.8* | 5091 | Mirena15 | ||
Vaginal ring | 2.4 | 2501 | NuvaRing17 | ||
Transdermal System | 2.9 | 3322 | Ortho Evra18 | ||
Injection | 1.2 | >3900 | Depo-Provera16 | ||
Libido decrease | Injectable combination male contraceptive | 4.1 | 320 | Behre et al 20168 | |
COC (1959) | 22 | 830 | Pincus et al 195919 | ||
Vaginal ring | 2 | 2501 | NuvaRing17 | ||
Injection | 5.5 | >3900 | Depo-Provera16 | ||
Libido increase | Injectable combination male contraceptive | 38.1 | 320 | Behre et al 20168 | |
COC (1959) | 20 | 830 | Pincus et al 195919 | ||
Pelvic pain | Injectable combination male contraceptive | 1.9 | 320 | Behre et al 20168 | |
COC | 5.6 | 4826 | Ortho Tri-Cyclen14 | ||
COC | 9.2 | 1723 | Ortho Tri-Cyclen Lo11 | ||
IUS | 22.6* | 5091 | Mirena15 | ||
Vaginal ring | 7.2 | 2501 | NuvaRing17 | ||
Transdermal system | 8.1 | 3322 | Ortho Evra18 | ||
Injection | 11.2 | >3900 | Depo-Provera16 | ||
Weight gain | Injectable combination male contraceptive | 3.8 | 320 | Behre et al 20168 | |
COC (1959) | 55 | 830 | Pincus et al 195919 | ||
COC | 2.4 | 1723 | Ortho Tri-Cyclen Lo11 | ||
Vaginal ring | 4.9 | 2501 | NuvaRing17 | ||
Transdermal system | 2.7 | 3322 | Ortho Evra18 | ||
Injection | 37.7 | >3900 | Depo-Provera16 | ||
Mood changes | Injectable combination male contraceptive | 31.7 | 320 | Behre et al 20168 | |
COC | 2.2 | 1056 | Yaz13 | ||
COC | 2.3 | 2837 | Yasmin12 | ||
COC | 3.8 | 4826 | Ortho Tri-Cyclen14 | ||
COC | 7.6 | 1723 | Ortho Tri-Cyclen Lo11 | ||
IUS | 6.4* | 5091 | Mirena15 | ||
Injection | 1.5 | >3900 | Depo-Provera16 | ||
Vaginal ring | 6.4 | 2501 | NuvaRing17 | ||
Transdermal system | 6.3 | 3322 | Ortho Evra18 | ||
Headache | Injectable combination male contraceptive | 5.3 | 320 | Behre et al 20168 | |
COC | 6.7 | 1056 | Yaz13 | ||
COC | 10.7 | 2837 | Yasmin12 | ||
COC | 33.6 | 4826 | Ortho Tri-Cyclen14 | ||
COC | 30.5 | 1723 | Ortho Tri-Cyclen Lo11 | ||
IUS | 16.3* | 5091 | Mirena15 | ||
Vaginal ring | 11.2 | 2501 | NuvaRing17 | ||
Transdermal system | 21.0 | 3322 | Ortho Evra18 |
*Crude incidence per person-years.
AE, adverse event; COC, combined oral contraceptive; IUS, intrauterine system.